BACKGROUND: There have been not much reports on the result of intralesional excision for giant cell tumors (GCTs) of the femoral head and neck because of its rarity. The purpose of this study is to review the results of patients managed with intralesional curettage for GCT of the femoral head and neck. METHODS: We retrospectively reviewed 12 patients with a GCT of the femoral head and/or neck. All of them were treated with curettage and followed up to monitor local recurrence and pulmonary metastasis. Mean duration of follow-up was 58.3 months. RESULTS: Although recurrence rate of the present study was rather high (41.7%, 5 of 12 hips), 9 of 12 hips (75%) were preserved at last follow-up including 2 hips that underwent repeat curettage, and functional outcomes of the preserved hips were satisfactory. CONCLUSION: It may be that curettage should be considered as a primary treatment of choice for GCTs of the femoral head and neck.
BACKGROUND: There have been not much reports on the result of intralesional excision for giant cell tumors (GCTs) of the femoral head and neck because of its rarity. The purpose of this study is to review the results of patients managed with intralesional curettage for GCT of the femoral head and neck. METHODS: We retrospectively reviewed 12 patients with a GCT of the femoral head and/or neck. All of them were treated with curettage and followed up to monitor local recurrence and pulmonary metastasis. Mean duration of follow-up was 58.3 months. RESULTS: Although recurrence rate of the present study was rather high (41.7%, 5 of 12 hips), 9 of 12 hips (75%) were preserved at last follow-up including 2 hips that underwent repeat curettage, and functional outcomes of the preserved hips were satisfactory. CONCLUSION: It may be that curettage should be considered as a primary treatment of choice for GCTs of the femoral head and neck.
Authors: Osman Emre Aycan; Sami Sökücü; Devrim Özer; Engin Çetinkaya; Yavuz Arıkan; Yavuz Selim Kabukçuoğlu Journal: Acta Orthop Traumatol Turc Date: 2018-11-12 Impact factor: 1.511